Format

Send to

Choose Destination
World J Gastroenterol. 2008 Jan 14;14(2):185-92.

Non-alcoholic fatty liver disease and the metabolic syndrome: an update.

Author information

1
Division of Gastroenterology and Hepatology, University of Missouri-Columbia, Columbia, MO 65212, United States.

Abstract

Sedentary lifestyle and poor dietary choices are leading to a weight gain epidemic in westernized countries, subsequently increasing the risk for developing the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD). NAFLD is estimated to affect approximate 30% of the general US population and is considered the hepatic manifestation of the metabolic syndrome. Recent findings linking the components of the metabolic syndrome with NAFLD and the progression to nonalcoholic steatohepatitis (NASH) will be reviewed; in particular, the role of visceral adipose tissue, insulin resistance, and adipocytokines in the exacerbation of these conditions. While no therapy has been proven effective for treating NAFLD/NASH, common recommendations will be discussed.

PMID:
18186553
PMCID:
PMC2675112
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center